Page last updated: 2024-11-02

pioglitazone and Metabolic Diseases

pioglitazone has been researched along with Metabolic Diseases in 8 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Metabolic Diseases: Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed)

Research Excerpts

ExcerptRelevanceReference
" Meanwhile, WY-14643 and pioglitazone, 2 drugs widely used for treating metabolic diseases, were employed to prevent oleate-induced disorders of macrophage phospholipid metabolism."4.02Metabolomics Insights into Oleate-Induced Disorders of Phospholipid Metabolism in Macrophages. ( Ai, XY; Chen, J; Gao, H; Huang, Q; Wu, Z; Yang, BC; Ye, G, 2021)
"Pioglitazone did not increase weight or produce any other significant side-effects."2.78Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. ( Bark, N; Davis, JM; Dwivedi, S; Hu, Q; Jin, H; Li, C; Lohr, J; Mortiere, C; Shekhar, A; Smith, RC, 2013)
"Pioglitazone treatment of KK-A(y) mice for 14 days significantly reduced the accumulation of inflammatory cells in ischemic myocardium, and infarct size 3 days after reperfusion compared to vehicle treatment (p<0."1.35Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders. ( Fuchigami, S; Hayasaki, T; Honda, T; Kaikita, K; Matsukawa, M; Ogawa, H; Sakashita, N; Sugiyama, S; Takeya, M; Tsujita, K, 2008)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (37.50)29.6817
2010's2 (25.00)24.3611
2020's3 (37.50)2.80

Authors

AuthorsStudies
Colca, JR1
Scherer, PE1
Ye, G1
Yang, BC1
Gao, H1
Wu, Z1
Chen, J1
Ai, XY1
Huang, Q1
Póvoa, VMO1
Delafiori, J1
Dias-Audibert, FL1
de Oliveira, AN1
Lopes, ABP1
de Paula, EV1
Pagnano, KBB1
Catharino, RR1
Lian, QX1
Deng, HZ1
Chen, KY1
Deng, H1
Foryst-Ludwig, A1
Clemenz, M1
Hohmann, S1
Hartge, M1
Sprang, C1
Frost, N1
Krikov, M1
Bhanot, S1
Barros, R1
Morani, A1
Gustafsson, JA1
Unger, T1
Kintscher, U1
Finsterer, J1
Stöllberger, C1
Smith, RC1
Jin, H1
Li, C1
Bark, N1
Shekhar, A1
Dwivedi, S1
Mortiere, C1
Lohr, J1
Hu, Q1
Davis, JM1
Honda, T1
Kaikita, K1
Tsujita, K1
Hayasaki, T1
Matsukawa, M1
Fuchigami, S1
Sugiyama, S1
Sakashita, N1
Ogawa, H1
Takeya, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia Treated With Antipsychotic Medication And Potential Effects on Cognitive Function[NCT00231894]Phase 456 participants (Actual)Interventional2005-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

2 Hour Glucose From Glucose Tolerance Test China Sample

difference between 2 hr glucose for GTT test at baseline vs after 3 months of drug treatment (NCT00231894)
Timeframe: between baseline and 3 months of study drug treatment

Interventionmg/dL (Least Squares Mean)
Pioglitazone-6.82
Placebo-40.72

2 Hour Glucose From Glucose Tolerance Test US Sample

difference between 2 hr glucose for GTT test at baseline vs after 3 months of drug treatment (NCT00231894)
Timeframe: between baseline and 3 months of study drug treatment

Interventionmg/dL (Least Squares Mean)
Pioglitazone-24.19
Placebo15.19

Change From Baseline in Serum Glucose at 3 Months ( 3 Months -Baseline) China Sample

(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment

Interventionmg/dL (Least Squares Mean)
Pioglitazone-13.33
Placebo-11.5

Change From Baseline in Serum Glucose at 3 Months (3 Months-baseline) US Sample

(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment

Interventionmg/dL (Least Squares Mean)
Pioglitazone0.02
Placebo24.20

Change From Baseline in Serum HDL at 3 Months (3 Months-baseline) China Site

(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment

Interventionmg/dL (Least Squares Mean)
Pioglitazone6.52
Placebo7.72

Change From Baseline in Serum HDL at 3 Months (3 Months-baseline) US Sample

serum high density lipoprotein (HDL) (NCT00231894)
Timeframe: pre-treatment and during 3 months of treatment

Interventionmg/dL (Least Squares Mean)
Piogltiazone4.62
Placebo-2.59

Change From Baseline in Serum Triglycerides at 3 Months ( 3 Months-baseline) US Sample

(NCT00231894)
Timeframe: pre-treatment and during 3 months of treatment

Interventionmg/dL (Least Squares Mean)
Pioglitazone-49.65
Placebo30.99

Change From Baseline in Serum Triglycerides at 3 Months (3 Months-baseline) China Sample

(NCT00231894)
Timeframe: pretreatment and during 3 months of drug treatment

Interventionmg/dL (Least Squares Mean)
Pioglitazone32.56
Placebo-79.12

Change in RBANS List Recognition Scores at 3 Months (3 Months-baseline) US Sample

The scale is Repeatable Battery for the Assessment to Neuropsychological Status (RBANS). This scale measure cognitive function in patients with schizophrenia. Range for list learning sub-score is 0 to 20 . Higher values indicate better performance. For change score (3 months -baseline) positive values indicate improved performance for this cognitive function and negative values indicate poorer performance on this cognitive function. (NCT00231894)
Timeframe: pre-treatment and 3 months of treatment

InterventionUnits on RBANS scale (Least Squares Mean)
Pioglitazone0.27
Placebo-1.11

Reviews

1 review available for pioglitazone and Metabolic Diseases

ArticleYear
The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease.
    Molecular metabolism, 2022, Volume: 55

    Topics: Adipose Tissue; Chronic Disease; COVID-19; Diabetes Mellitus, Type 2; Humans; Inflammation; Insulin;

2022

Trials

2 trials available for pioglitazone and Metabolic Diseases

ArticleYear
Metabolic shift of chronic myeloid leukemia patients under imatinib-pioglitazone regimen and discontinuation.
    Medical oncology (Northwood, London, England), 2021, Jul-24, Volume: 38, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female; Follow-Up St

2021
Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study.
    Schizophrenia research, 2013, Volume: 143, Issue:1

    Topics: Adult; Analysis of Variance; Antipsychotic Agents; Antisocial Personality Disorder; Case-Control Stu

2013

Other Studies

5 other studies available for pioglitazone and Metabolic Diseases

ArticleYear
Metabolomics Insights into Oleate-Induced Disorders of Phospholipid Metabolism in Macrophages.
    The Journal of nutrition, 2021, 03-11, Volume: 151, Issue:3

    Topics: Animals; Chromatography, Liquid; Lipid Metabolism; Macrophages; Mass Spectrometry; Metabolic Disease

2021
Role of Peroxisome Proliferator-Activated Receptor (PPARγ) in Metabolic Disorders in SGA with Catch-Up Growth.
    Obesity (Silver Spring, Md.), 2018, Volume: 26, Issue:1

    Topics: Adult; Animals; Female; Humans; Infant, Newborn; Infant, Small for Gestational Age; Male; Metabolic

2018
Metabolic actions of estrogen receptor beta (ERbeta) are mediated by a negative cross-talk with PPARgamma.
    PLoS genetics, 2008, Jun-27, Volume: 4, Issue:6

    Topics: Adipocytes; Animals; Cell Differentiation; Estrogen Receptor beta; Female; Gene Expression; Glucose;

2008
Pioglitazone-induced heart failure in a patient with restrictive cardiomyopathy and metabolic myopathy.
    Clinical research in cardiology : official journal of the German Cardiac Society, 2009, Volume: 98, Issue:4

    Topics: Cardiomyopathy, Restrictive; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypoglycemic Agents;

2009
Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disorders.
    Journal of molecular and cellular cardiology, 2008, Volume: 44, Issue:5

    Topics: Animals; Body Weight; Cells, Cultured; Gene Expression Regulation; Heart Ventricles; Inflammation; M

2008